Pharmafile Logo

Badger Associates Limited

Welcome to Badger Associates Recruitment Consultants for Norwich, Norfolk and East Anglia.We provide you with the most comprehensive site for Specialist Jobs in Norfolk, Jobs in Suffolk and Jobs in Cambridge. Badger Associates is a boutique HR Consultancy and Recruitment company covering East Anglia &  catering for the most discerning employers and working with the best senior and specialist candidates. Rated the best Senior and Specialist Head Hunter in the region for the past four years.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors with over 6 million members across M3-owned networks and an…

View Profile

Company Details

Pottergate Street, Aslacton, Norwich, Norfolk, NR15 2JU, United Kingdom
+44 (0)1508 536013

 Latest Content from PMHub 

CMI Media Group and Compas Earn 2025 Great Place To Work Certification

Press Releases | September 19, 2025 | CMI Media Group

PHILADELPHIA, PA – Strategic media healthcare agencies CMI Media Group & Compas, a WPP company (NYSE: WPP), are proud to be Certified™ by Great Place To Work® for the third year in...

solli – CMI’s International Man of Media

Press Releases | September 19, 2025 | CMI Media Group

Matt Durham, VP, Global, anticipated pharma’s global media boom. Now he’s leading CMI Media Group’s push to broaden its market coverage. This new profile article focusing on Global VP Matt...

PharmiWeb – Why Pharmaceutical Brands Must Act On Digital Trends Now

Press Releases | September 19, 2025 | CMI Media Group

The ASCO Conference has a global impact; a new PharmiWeb byline by Calum Griffin, Senior Global Engagement Planner inspired by the conference shares that the pharma marketing landscape has radically...

Genetic Digital Wins Silver at PM Society Digital Awards for Epilepsy Meds Clinical Support App

Press Releases | September 18, 2025 | Genetic Digital

Genetic Digital wins Silver at the PM Society Digital Awards for Epilepsy Meds, a clinical support app developed with Desitin and ChangeMed to aid patient-specific prescribing in epilepsy care.

AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

Press Releases | September 17, 2025 | Innovative Trials

Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

Lucid Strategy Consulting: Empowering Next-Generation Solutions for Life Sciences

Lucid Group announces the evolution of its consulting division, Lucid Strategy Consulting, setting a new standard for deep-domain, knowledge-led consulting solutions for life sciences. We have brought together two Lucid...

Streamlining European expansion for cell and gene therapies

White Papers and Resources | September 16, 2025 | Uniphar

Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...

Current CGT landscape and future outlook  

White Papers and Resources | September 16, 2025 | Uniphar

What makes CGT unique  Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...

Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals 

White Papers and Resources | September 16, 2025 | Uniphar

This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...

Navigating the complexities of launch preparation for Cell and Gene Therapy

White Papers and Resources | September 16, 2025 | Uniphar

Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...